Company intelligence / Profile preview

Luminist Labs

Ownership: Private
Employees: ~2
Development stage: Other

Overview

Luminist Labs developed a novel, non-invasive diagnostic test/platform for early detection and staging of liver fibrosis and NASH. The technology was acquired by DiscernDx in 2020 to be integrated into their precision medicine solutions targeting chronic metabolic diseases. No specific clinical trial results are published; the value lies in its scalable, low-cost approach compared to invasive biopsy.

Therapeutic areas: Gastroenterology
Modalities: Diagnostic platform (non-invasive diagnostics)Genomics-based diagnostics
Industry: Molecular Diagnostics

Partnerships

Integrated with DiscernDx post-acquisition

Beyond the preview

Go deeper on Luminist Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Luminist Labs.

Explore the full profile